Anzeige
Mehr »
Login
Dienstag, 05.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
300% Aktienanstieg war nur der Vorgeschmack – Warum diese Kupferstory noch besser wird!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
484 Leser
Artikel bewerten:
(1)

BlackRock Greater Europe Investment Trust Plc - Portfolio Update

BlackRock Greater Europe Investment Trust Plc - Portfolio Update

PR Newswire

The information contained in this release was correct as at 30 November 2021. Information on the Company's up to date net asset values can be found on the London Stock Exchange website at:

https://www.londonstockexchange.com/exchange/news/market-news/market-news-home.html.

BLACKROCK GREATER EUROPE INVESTMENT TRUST PLC (LEI - 5493003R8FJ6I76ZUW55)

All information is at 30 November 2021 and unaudited.

Performance at month end with net income reinvested

One
Month
Three
Months
One
Year
Three
Years
Launch
(20 Sep 04)
Net asset value (undiluted)0.3%0.5%35.1%105.8%817.2%
Net asset value* (diluted)0.3%0.5%35.6%105.7%817.6%
Share price1.2%1.2%41.1%122.6%852.5%
FTSE World Europe ex UK-1.7%-2.4%15.7%41.2%361.7%

* Diluted for treasury shares and subscription shares.
Sources: BlackRock and Datastream

At month end

Net asset value (capital only):676.28p
Net asset value (including income):677.32p
Net asset value (capital only)1:676.28p
Net asset value (including income)1:677.32p
Share price:696.00p
Premium to NAV (including income):2.8%
Premium to NAV (including income)1:2.8%
Net gearing:9.4%
Net yield2:0.9%
Total assets (including income):£676.5m
Ordinary shares in issue3:99,885,411
Ongoing charges4:1.02%

1 Diluted for treasury shares.
2 Based on a final dividend of 4.55p per share and an interim dividend of 1.75p per share for the year ended 31 August 2021.
3 Excluding 17,573,527 shares held in treasury.
4 Calculated as a percentage of average net assets and using expenses, excluding interest costs, after relief for taxation, for the year ended 31 August 2021.

Sector AnalysisTotal Assets (%)
Industrials24.1
Technology22.2
Health Care17.6
Consumer Discretionary16.9
Financials8.6
Consumer Staples4.7
Energy3.7
Basic Materials3.1
Net Current Liabilities-0.9
-----
100.0
=====
Country AnalysisTotal Assets (%)
Switzerland23.1
Netherlands17.9
Denmark15.9
France13.1
Sweden8.0
United Kingdom5.7
Italy4.6
Russia3.9
Ireland2.0
Spain1.8
Finland1.7
Poland1.5
Greece0.9
Germany0.8
Net Current Liabilities-0.9
-----
100.0
=====

Top 10 holdingsCountryFund %
ASMLNetherlands7.1
LVMH Moët HennessyFrance6.0
SikaSwitzerland5.3
Lonza GroupSwitzerland5.3
Novo NordiskDenmark4.7
RELXUnited Kingdom4.2
DSVDenmark4.1
Hermes InternationalFrance3.2
Royal UnibrewDenmark3.1
IMCDNetherlands3.1

Commenting on the markets, Stefan Gries, representing the Investment Manager noted:

During the month, the Company's NAV rose by 0.3% and the share price by 1.2%. For reference, the FTSE World Europe ex UK Index fell by 1.7% during the period.

Europe ex UK markets fell during November as fears about the latest Covid variant 'Omicron' caused a set-back in risk assets globally. All sectors in the reference index, except for telecommunications, delivered negative returns. In particular, energy, financials and technology were the weakest sectors during the month.

The Company outperformed its reference index during the month, mainly driven by strong stock selection while sector allocation was slightly negative.

In sector terms, the Company's lower allocation to financials and higher allocation to health care and industrials was positive. Our overweight exposure to technology was negative; however, this was significantly offset by strong stock selection. Zero exposure to defensive sectors such as telecommunications and utilities was negative.

The industrials sector was the largest contributor to relative returns. In particular, Sika was the top performer over the month. Shares rose after the company announced the acquisition of MBCC, the former construction chemicals business of BASF. We believe the deal will be circa 20% accretive in year 1, will further improve Sika's competitive position and will bring cross-selling synergies. The deal has been financed conservatively and we expect Sika to deleverage relatively quickly.

The Company also benefited from strong stock picking within consumer goods. French luxury group Hermes was amongst the best performers, benefiting from strong demand and carefully managed product sell throughs. Our holding in Ferrari also contributed positively as shares rose following strong Q3 results highlighting strong group order intake. Furthermore, the luxury car manufacturer presented their new car, the Daytona SP3, which is the second of its Icona series. First deliveries of the limited supply of 599 cars are expected towards the end of next year. The car has significantly higher margins than its predecessor, the Monza car, and sold out immediately.

The Company's semiconductor-exposed stocks such as BE Semiconductor, VAT Group and ASML all aided returns. BE Semiconductor for example saw strong performance on the back of good results at the end of October. We believe industry trends are likely to remain favourable for BE Semiconductor as the packaging equipment which the company provides becomes increasingly important.

However, our holding in Royal Unibrew weighed on returns. The company posted strong Q3 organic growth but also some margin compression as a result of higher freight costs and, consequently, operating profit undershot expectations. Our position in Allfunds was also amongst the largest detractors despite no stock specific news released over the period.

The Company's holding in Neste Oil experienced volatility, partially driven by negative performance of the energy sector in general and partially driven by concerns over rising competition. Whilst the worries around competition are not new, we believe Neste's renewable process is highly complex and the company is able to use several types of feedstock to produce renewable diesel which is quite unique.

At the end of the period, the Company had a higher allocation than the reference index towards technology, industrials, consumer discretionary and health care, and was neutral energy. The Company had an underweight allocation to financials, consumer staples, utilities, telecoms, real estate and basic materials.

Outlook

We see recent market strength persisting over the coming months, aided by better virus testing capabilities, a successful vaccine rollout and a resilient global consumer, alongside continued accommodative fiscal and monetary policy. This market recovery is unlikely to be equal across all sectors: some companies still lack pricing power and are unable to reinstate dividends; others, however, such as travel exposed stocks, could see a meaningfully brighter 2022. Inflation may be on the horizon, but rates will likely remain low. A period of prolonged negative real rates and higher nominal growth is needed to allow governments globally to work their way out of the post pandemic debt overhang. We see this as being a supportive backdrop for equities overall.

20 December 2021

ENDS

Latest information is available by typing www.blackrock.com/uk/brge on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager's website nor the contents of any website accessible from hyperlinks on the Manager's website (or any other website) is incorporated into, or forms part of, this announcement.

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.